ALNY - Alnylam Pharmaceuticals Inc Stock Price, Fair Value and News

234.86USD-3.02 (-1.27%)Market Closed

Market Summary

USD234.86-3.02

Market Closed

-1.27%

ALNY Alerts

7 major insider sales recently.

ALNY Stock Price

View Fullscreen

ALNY RSI Chart

ALNY Valuation

Market Cap

29.7B

Price/Earnings (Trailing)

-89.46

Price/Sales (Trailing)

14.83

EV/EBITDA

-209.08

Price/Free Cashflow

232.41

ALNY Price/Sales (Trailing)

ALNY Profitability

EBT Margin

-16.21%

Return on Equity

151.44%

Return on Assets

-8.68%

Free Cashflow Yield

0.43%

ALNY Fundamentals

ALNY Revenue

Revenue (TTM)

2.0B

Rev. Growth (Yr)

54.82%

Rev. Growth (Qtr)

12.42%

ALNY Earnings

Earnings (TTM)

-332.1M

Earnings Growth (Yr)

62.13%

Earnings Growth (Qtr)

52.18%

Breaking Down ALNY Revenue

Last 7 days

0.0%

Last 30 days

-0.9%

Last 90 days

66.0%

Trailing 12 Months

22.0%

How does ALNY drawdown profile look like?

ALNY Financial Health

Current Ratio

3.17

Debt/Equity

-4.66

Debt/Cashflow

0.19

ALNY Investor Care

Shares Dilution (1Y)

1.58%

Diluted EPS (TTM)

-2.65

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	2.0B	0	0	0
2023	1.1B	1.2B	1.7B	1.8B
2022	880.0M	884.2M	960.9M	1.0B
2021	570.9M	687.5M	749.3M	844.3M
2020	285.9M	345.2M	401.0M	492.9M
2019	86.3M	101.1M	169.1M	219.8M
2018	92.9M	106.8M	91.8M	74.9M
2017	58.8M	66.0M	69.4M	89.9M
2016	29.9M	29.9M	37.3M	47.2M
2015	60.8M	62.2M	57.6M	41.1M
2014	36.8M	35.4M	37.4M	50.6M
2013	64.8M	52.6M	44.8M	47.2M
2012	82.4M	82.7M	78.7M	66.7M
2011	96.4M	90.4M	83.5M	82.8M
2010	100.0M	102.1M	105.5M	100.0M
2009	0	97.6M	99.1M	100.5M
2008	0	0	0	96.2M

Get all data in R, Python etc through our Historical Stock Data APIs

About Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

CEO	Dr. Yvonne L. Greenstreet M.B.A., MBA, MBChB
WEBSITE	alnylam.com
INDUSTRY	Biotechnology
EMPLOYEES	2002

Alnylam Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Alnylam Pharmaceuticals Inc? What does ALNY stand for in stocks?

ALNY is the stock ticker symbol of Alnylam Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Alnylam Pharmaceuticals Inc (ALNY)?

As of Thu Jul 25 2024, market cap of Alnylam Pharmaceuticals Inc is 30.09 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ALNY stock?

You can check ALNY's fair value in chart for subscribers.

Is Alnylam Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether ALNY is over valued or under valued. Whether Alnylam Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Alnylam Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ALNY.

What is Alnylam Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jul 25 2024, ALNY's PE ratio (Price to Earnings) is -90.61 and Price to Sales (PS) ratio is 15.02. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ALNY PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Alnylam Pharmaceuticals Inc's stock?

In the past 10 years, Alnylam Pharmaceuticals Inc has provided 0.161 (multiply by 100 for percentage) rate of return.